Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
307.4 USD | +0.51% | +0.52% | +6.74% |
05-28 | US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment | RE |
05-28 | Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.74% | 164B | |
+42.60% | 739B | |
+32.34% | 598B | |
-5.74% | 353B | |
+17.79% | 318B | |
+3.37% | 285B | |
+16.47% | 240B | |
+9.26% | 210B | |
-5.07% | 206B | |
+1.81% | 162B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Morgan Stanley Boosts Price Target on Amgen to $282 From $279, Calls Q3 'Solid,' Maintains Overweight Rating